J&J packs up HIV vaccine after failing phase 3 trial
Phase 2 attrition jumps amid widespread scale-back in overall clinical trial activity
PwC predicts 'flurry' of $5B to $15B biotech deals in 2023
Bluebird hopes to raise upwards of $100M by selling shares
*please scroll down for all the latest news*
